Corvus Pharma (CRVS) – Hot FDA News
-
Corvus Pharma (CRVS) Discontinues Phase 3 Study of Mupadolimab for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
-
Corvus Pharma (CRVS) Reports Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
-
Back to CRVS Stock Lookup